Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06793059 · ClinicalTrials.gov registry record · NA
Evaluation of Flow Diverter Technology Device for Intracranial Aneurysm (SHIELD)
A NA study of Aneurysm, sponsored by Jacobs institute.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06793059: Recruiting NA study of Aneurysm, sponsored by Jacobs institute.
NCT06793059 is a NA study of Aneurysm that is actively recruiting participants, run by Jacobs institute. The registered enrollment target is 10 participants, below the 17,095-participant average among 6 other Aneurysm trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06793059, a NA study of Aneurysm, is actively recruiting participants, sponsored by Jacobs institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The Jacobs Institute is participating in a study designed to collect prospective clinical evidence to evaluate the approved use of the Pipeline™ Flex Embolization Device with Shield Technology™ for the endovascular treatment of adults (22 years of age or older) with wide-necked intracranial aneurysms
Primary Outcome
The Pipeline™ Flex Embolization Device with Shield Technology™ for the endovascular treatment of adults (22 years of age or older) with large or giant wide-necked intracranial aneurysms (IAs) in the internal carotid artery from the petrous to the superior hypophyseal segments. The Pipeline™ Flex Embolization Device with Shield Technology™ is also indicated for use in the internal carotid artery up to the terminus for the endovascular treatment of adults (22 years of age or older) with small and
Conditions Studied
Interventions
- DEVICE SHIELD
Study Locations (1)
New York
- Jacobs Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-01-01 |
| Est. Completion | 2027-01-01 |
| Phase | NA |
What NCT06793059 shows while recruiting
NCT06793059 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 17,095-participant average among 6 other Aneurysm trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Aneurysm appearing as the primary indexed condition, and to 1 intervention - of which SHIELD is the first listed.
NCT06793059 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06793059 about?
NCT06793059 is a clinical study titled "Evaluation of Flow Diverter Technology Device for Intracranial Aneurysm (SHIELD)". The Jacobs Institute is participating in a study designed to collect prospective clinical evidence to evaluate the approved use of the Pipeline™ Flex Embolization Device with Shield Technology™ for the endovascular treatment of adults (22 years of age or older) with wide-necked intracranial aneurysm...
What is the current status of trial NCT06793059?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2025-01-01. Estimated completion is 2027-01-01.
What conditions does trial NCT06793059 study?
This clinical trial studies the following conditions: Aneurysm.
What interventions are being tested in trial NCT06793059?
The interventions under investigation include: SHIELD (DEVICE).
Who is sponsoring clinical trial NCT06793059?
This trial is sponsored by Jacobs institute, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06793059 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aneurysm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
RECRUITING · NA
-
An Observational Study On TheAccuracy Of Whole-Body Magnetic Resonance Imaging (Wb-Mri) ScreeningTo Predict Clinically Significant Diagnoses In General Population Subjects Interested In Proactive And Advanced General Preventive Healthcare.
RECRUITING
-
Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms
RECRUITING · Phase 1
-
PANTHER Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches
RECRUITING
-
Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial
COMPLETED · Phase 2
-
Doppler Flow Wires in Cerebral Angiography
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI